Latest Period
Q2 2026
Security Snapshot
Werewolf Therapeutics, Inc. - Common Stock, $0.0001 par value per share (HOWL) Institutional Ownership
CUSIP: 95075A107
13F Institutional Holders and Ownership History from Q2 2021 to Q2 2026
Institutions Reporting
45
Shares (Excl. Options)
10,864,466
Price
$0.36
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- HOWL on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 10,864,466
- Total 13F value
- $3,912,160
- Portfolio coverage rank
- 0%
- Share change
- -3,135,438
- Value change
- -$1,467,220
- Number of holders
- 45
- Shares outstanding
- 48,427,829
- SEC-reported price per share
- $0.45
- Insider filing price
- $0.45
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- HOWL - Werewolf Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 95075A107.
- 45 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 47 to 45 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $11,653,844 to $3,912,160.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 45 institutions filings for Q2 2026.
Security key
95075A107
Latest holder period
Q2 2026
13F holders
45
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
HOWL full holder history
Werewolf Therapeutics, Inc. SEC filings
Werewolf Therapeutics, Inc. company facts
Werewolf Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 95075A107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
HOWL
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 4.1% | -32% | $734,650 | -$344,174 | 1,985,541 | -32% | RA Capital Management, L.P. | 30 Jun 2026 |
| MPM BioVentures 2014, L.P. | 3.8% | -32% | $1,680,514 | -$719,307 | 1,826,646 | -30% | ANSBERT GADICKE | 08 May 2026 |
| Longwood Fund III, L.P. | 3.5% | $955,937 | 1,677,082 | Longwood Fund III GP, LLC | 31 Dec 2025 | |||
| PFM Health Sciences, LP | 0.9% | -80% | $437,210 | -$2,729,747 | 401,110 | -86% | PFM Health Sciences, LP | 30 Jun 2025 |
As of 30 Jun 2026, 45 institutional investors reported holding 10,864,466 shares of Werewolf Therapeutics, Inc. - Common Stock, $0.0001 par value per share (HOWL). This represents 22% of the company’s total 48,427,829 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
22%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 4.9% | 2,387,744 | -64% | 0.01% | $859,349 |
| Balyasny Asset Management L.P. | 3.7% | 1,790,089 | 0% | $644,253 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 1,217,976 | 0% | 0% | $438,471 |
| RENAISSANCE TECHNOLOGIES LLC | 1.4% | 674,632 | +31% | 0% | $242,800 |
| Lynx1 Capital Management LP | 1.4% | 657,786 | 0% | 0.03% | $236,737 |
| SPHERA FUNDS MANAGEMENT LTD. | 1.3% | 626,810 | 0% | 0.03% | $225,589 |
| DC Funds, LP | 1.2% | 589,102 | 0% | 17% | $212,018 |
| Verdad Advisers, LP | 0.72% | 348,709 | +1072% | 0.12% | $125,500 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.69% | 335,815 | -14% | 0% | $120,895 |
| BANK OF AMERICA CORP /DE/ | 0.64% | 311,502 | +18% | 0% | $111,829 |
| XTX Topco Ltd | 0.56% | 271,478 | +433% | 0% | $97,705 |
| JANE STREET GROUP, LLC | 0.52% | 251,837 | +204% | 0% | $90,637 |
| UBS Group AG | 0.45% | 215,838 | +223% | 0% | $77,702 |
| VANGUARD FIDUCIARY TRUST CO | 0.33% | 157,726 | 0% | 0% | $56,781 |
| STATE STREET CORP | 0.25% | 119,168 | 0% | 0% | $42,889 |
| Squarepoint Ops LLC | 0.21% | 103,242 | 0% | $37,157 | |
| BlackRock, Inc. | 0.21% | 101,573 | -0.03% | 0% | $36,556 |
| Rangeley Capital, LLC | 0.21% | 100,000 | 0.04% | $35,990 | |
| NORTHERN TRUST CORP | 0.18% | 86,851 | 0% | 0% | $31,258 |
| Alyeska Investment Group, L.P. | 0.18% | 86,554 | 0% | 0% | $31,151 |
| MPM BIOIMPACT LLC | 0.17% | 80,142 | -93% | 0% | $28,851 |
| MILLENNIUM MANAGEMENT LLC | 0.13% | 62,055 | -53% | 0% | $22,334 |
| Virtu Financial LLC | 0.09% | 45,467 | 0% | $16,000 | |
| TWO SIGMA INVESTMENTS, LP | 0.06% | 27,300 | 0% | $9,825 | |
| GSA CAPITAL PARTNERS LLP | 0.06% | 27,146 | 0% | $10,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
21
Latest
Q2 2026
Rows shown
1-21 of 21
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 10,864,466 | $3,912,160 | -$1,467,220 | $0.36 | 45 |
| 2026 Q1 | 13,999,904 | $11,653,844 | -$532,173 | $0.83 | 47 |
| 2025 Q4 | 14,735,208 | $9,335,513 | -$2,241,745 | $0.63 | 49 |
| 2025 Q3 | 21,108,242 | $41,572,612 | -$2,103,204 | $1.97 | 62 |
| 2025 Q2 | 22,335,758 | $24,343,246 | -$5,335,449 | $1.09 | 65 |
| 2025 Q1 | 27,445,533 | $26,679,025 | -$940,155 | $0.97 | 70 |
| 2024 Q4 | 28,177,146 | $41,701,476 | -$7,785,512 | $1.48 | 71 |
| 2024 Q3 | 32,205,548 | $68,274,106 | -$1,018,677 | $2.12 | 68 |
| 2024 Q2 | 32,469,409 | $79,220,415 | -$5,272,473 | $2.44 | 70 |
| 2024 Q1 | 32,251,087 | $208,968,732 | +$29,830,206 | $6.48 | 59 |
| 2023 Q4 | 27,669,999 | $106,805,060 | +$14,923,168 | $3.86 | 41 |
| 2023 Q3 | 23,882,934 | $51,107,776 | -$364,729 | $2.14 | 34 |
| 2023 Q2 | 24,045,139 | $73,334,928 | +$110,396 | $3.05 | 36 |
| 2023 Q1 | 24,035,818 | $62,491,910 | +$8,454,617 | $2.60 | 37 |
| 2022 Q4 | 20,890,957 | $42,845,289 | -$4,124,677 | $2.05 | 37 |
| 2022 Q3 | 20,956,559 | $94,490,128 | +$8,517,407 | $4.51 | 39 |
| 2022 Q2 | 19,071,418 | $78,002,023 | +$194,911 | $4.09 | 39 |
| 2022 Q1 | 18,982,797 | $83,522,100 | -$5,015,169 | $4.40 | 47 |
| 2021 Q4 | 19,103,784 | $227,525,761 | -$818,751 | $11.91 | 50 |
| 2021 Q3 | 18,418,726 | $316,117,290 | -$12,884,754 | $17.16 | 41 |
| 2021 Q2 | 19,169,179 | $334,041,360 | +$334,041,360 | $17.44 | 44 |